Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $144.12, a high estimate of $155 ...

Merck, a leading science and technology company, and Siemens deepened their cooperation aimed at taking smart manufacturing ...

(MRK) said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda in combination with pemetrexed and platinum chemotherapy as a first-line treatment for ...

Under a MOU signed between both the parties, Merck and Siemens have decided to expand their cooperation in Smartfacturing.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In a report released on September 11, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – ...

Yes. I think it depends on the therapeutic area. So if I look at where we are today, the two products we just talked about are very different. So if I think through KEYTRUDA, roughly around 60% of my ...